BiotechTube

Tolvaptan + placebo

Phase 3Withdrawn
0 watching 0 views this week📈 Rising
76
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Acute Heart Failure

Conditions

Acute Heart Failure

Trial Timeline

— → —

NCT ID
NCT01733134

About Tolvaptan + placebo

Tolvaptan + placebo is a phase 3 stage product being developed by Thermo Fisher Scientific for Acute Heart Failure. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01733134. Target conditions include Acute Heart Failure.

Hype Score Breakdown

Clinical
27
Activity
18
Company
9
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01733134Phase 3Withdrawn

Competing Products

20 competing products in Acute Heart Failure

See all competitors
ProductCompanyStageHype Score
AFM28AffimedPhase 1
25
TRV130 1.5 mg + TRV130 3 mg + TRV130 4.5 mg + Morphine 10 mg + PlaceboTrevenaPhase 1
25
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + PlaceboTrevenaPhase 2
44
Oliceridine + Placebo + MorphineTrevenaPhase 3
69
Oliceridine + Placebo + MorphineTrevenaPhase 3
69
TRV130TrevenaPhase 3
69
TRV130 + Morphine + PlaceboTrevenaPhase 2
44
Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimenCSPC Pharmaceutical Group LimitedPhase 2
51
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T CellsCSPC Pharmaceutical Group LimitedPhase 2
51
SPT-07A injectionSinopharmPhase 3
76
PRGN-3006 T CellsPrecigenPhase 1
28
BisantreneRace OncologyPhase 2
44
Bisantrene Dihydrochloride (high dose) + Bisantrene Dihydrochloride (low dose) + Cytarabine Hydrochloride + Decitabine and cedazuridineRace OncologyPhase 1
25
Bisantrene + Fludarabine + ClofarabineRace OncologyPhase 2
44
ZN-d5 ZN-c3 + ZN-c3Zentalis PharmaceuticalsPhase 1/2
33
ZN-d5Zentalis PharmaceuticalsPhase 1
25
VIP943 (QW) + VIP943 (BIW)Vincerx PharmaPhase 1
25
LY2523355Eli LillyPhase 1
33
TomivosertibeFFECTOR TherapeuticsPhase 1
25
gemtuzumab ozogamycinChugai PharmaceuticalPhase 3
77

Other Products from Thermo Fisher Scientific

zamtocabtagene autoleucel (MB-CART2019.1)Phase 2
51
BGP-15 100 mg QD + BGP-15 100 mg BID + Placebo BID + BGP-15 200 mg QD + BGP-15 200 mg BID + BGP-15 400 mg QDPhase 2
51
LR-ESHAP (lenalidomide 5 mg) + LR-ESHAP (lenalidomide 10 mg) + LR-ESHAP (lenalidomide 15 mg) + LR-ESHAP (lenalidomide 20 mg)Phase 1/2
40
ShA9 Topical Gel + Hydrocortisone Ointment + Clobetasol Ointment + Fluocinonide Ointment + Placebo (Vehicle) Topical GelPhase 1
32
Olokizumab + Omeprazole + Caffeine + Warfarin+ Vitamin K + MidazolamPhase 1
32